Deprenyl is metabolized to methamphetamine and amphetamine in man.
作者信息
Reynolds G P, Elsworth J D, Blau K, Sandler M, Lees A J, Stern G M
出版信息
Br J Clin Pharmacol. 1978 Dec;6(6):542-4. doi: 10.1111/j.1365-2125.1978.tb00883.x.
Abstract
摘要
相似文献
1
Deprenyl is metabolized to methamphetamine and amphetamine in man.在人体中，司来吉兰会代谢为甲基苯丙胺和苯丙胺。
Br J Clin Pharmacol. 1978 Dec;6(6):542-4. doi: 10.1111/j.1365-2125.1978.tb00883.x.
2
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.（-）司来吉兰代谢为苯丙胺和甲基苯丙胺可能是其治疗益处的原因：一项生化评估。
Neurology. 1982 May;32(5):503-9. doi: 10.1212/wnl.32.5.503.
3
Determination of the amine metabolites of selegiline in biological fluids by capillary gas chromatography.
J Chromatogr. 1990 Apr 27;527(1):163-8. doi: 10.1016/s0378-4347(00)82095-2.
4
Fungal metabolism of (-)-deprenyl and pargyline.（-）-司来吉兰和帕吉林的真菌代谢
Life Sci. 1981 Nov 9;29(19):1951-8. doi: 10.1016/0024-3205(81)90603-2.
5
Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study.通过手性毛细管电泳评估司来吉兰、甲基苯丙胺和苯丙胺对映体的N-氧化：一项体外代谢研究。
Electrophoresis. 2004 Aug;25(16):2866-75. doi: 10.1002/elps.200406023.
6
Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
Xenobiotica. 1986 Feb;16(2):129-36. doi: 10.3109/00498258609043515.
7
Metabolic transformation of deprenyl enantiomers in rats.
Neurobiology (Bp). 1999;7(2):247-54.
8
Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research.
J Neural Transm Suppl. 1996;48:61-73. doi: 10.1007/978-3-7091-7494-4_6.
9
The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.（-）-司来吉兰的苯丙胺代谢产物对其抗帕金森病特性的作用。
J Neural Transm. 1982;54(1-2):105-10. doi: 10.1007/BF01249283.
10
Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.多次小剂量给予（-）司来吉兰可增强大脑中的儿茶酚胺能活性并降低5-羟色胺能活性，且这些作用与单胺氧化酶-B抑制无关。
Arch Int Pharmacodyn Ther. 1994 Jul-Aug;328(1):1-15.
引用本文的文献
1
Kinetic modeling of the monoamine oxidase-B radioligand [F]SMBT-1 in human brain with positron emission tomography.正电子发射断层扫描研究单胺氧化酶-B 放射性配体[F]SMBT-1 在人脑中的动力学模型。
J Cereb Blood Flow Metab. 2024 Nov;44(11):1262-1276. doi: 10.1177/0271678X241254679. Epub 2024 May 12.
2
Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease.雷沙吉兰不会加重早期或轻度帕金森病患者的自主血压调节异常。
Clin Park Relat Disord. 2021 Dec 13;6:100124. doi: 10.1016/j.prdoa.2021.100124. eCollection 2022.
3
The nitrosoamphetamine metabolite is accommodated in the active site of human hemoglobin: Spectroscopy and crystal structure.亚硝基苯丙胺代谢物可容纳于人血红蛋白的活性部位：光谱和晶体结构。
J Inorg Biochem. 2020 Dec;213:111262. doi: 10.1016/j.jinorgbio.2020.111262. Epub 2020 Sep 29.
4
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology.精神科与神经科中MAO-A和MAO-B的抑制剂
Front Pharmacol. 2016 Oct 18;7:340. doi: 10.3389/fphar.2016.00340. eCollection 2016.
5
The Role of Metabolites of Antidepressants in the Treatment of Depression.抗抑郁药代谢物在抑郁症治疗中的作用。
CNS Drugs. 1997 Apr;7(4):273-312. doi: 10.2165/00023210-199707040-00003.
6
Monoamine reuptake inhibitors in Parkinson's disease.单胺再摄取抑制剂在帕金森病中的应用。
Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25.
7
BJCP 40th anniversary: moving forward, looking back.美国啤酒酿造者协会（BJCP）成立40周年：回顾往昔，展望未来。
Br J Clin Pharmacol. 2014 Dec;78(6):1175-84. doi: 10.1111/bcp.12520.
8
Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis.司来吉兰在减轻腹膜炎脓毒症大鼠器官功能障碍方面的佐剂潜力。
PLoS One. 2014 Sep 30;9(9):e108455. doi: 10.1371/journal.pone.0108455. eCollection 2014.
9
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.氘取代的左旋多巴在帕金森病动物模型中显示出增强的行为效力和多巴胺输出：与左旋多巴和单胺氧化酶B抑制剂产生的效果比较。
J Neural Transm (Vienna). 2015 Feb;122(2):259-72. doi: 10.1007/s00702-014-1247-6. Epub 2014 Jun 7.
10
PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.PINK1 杂合突变诱导多巴胺依赖的突触可塑性的细微改变。
Mov Disord. 2014 Jan;29(1):41-53. doi: 10.1002/mds.25724. Epub 2013 Oct 25.
本文引用的文献
1
Biochemical theories of schizophrenia. I.精神分裂症的生化理论。一。
Science. 1959 Jun 5;129(3362):1528-32. doi: 10.1126/science.129.3362.1528.
2
Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").
Acta Med Acad Sci Hung. 1967;23(3):289-95.
3
Urinary excretion of methylamphetamine in man.
Nature. 1965 Jun 19;206(990):1260-1. doi: 10.1038/2061260a0.
4
Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250).苯基异丙基甲基丙炔胺（E-250）光学异构体的比较药理学分析
Acta Physiol Acad Sci Hung. 1967;32(4):377-87.
5
Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man.苯丙胺对酪胺升压反应的影响：人体中苯丙胺形成对羟基去甲麻黄碱的过程。
Clin Pharmacol Ther. 1970 Sep-Oct;11(5):656-64. doi: 10.1002/cpt1970115656.
6
Phenethylamines in brain and liver of rats with experimentally induced phenylketonuria-like characteristics.具有实验性诱导的苯丙酮尿症样特征的大鼠脑和肝脏中的苯乙胺类物质。
Biochem J. 1973 Jan;132(1):95-100. doi: 10.1042/bj1320095.
7
Amphetamines in the treatment of Parkinson's disease.苯丙胺类药物在帕金森病治疗中的应用
J Neurol Neurosurg Psychiatry. 1975 Mar;38(3):232-7. doi: 10.1136/jnnp.38.3.232.
8
Identification and distribution of benzylamine in tissue extracts isolated from rats pretreated with pargyline.帕吉林预处理大鼠分离的组织提取物中苄胺的鉴定与分布
Biochem Pharmacol. 1976 Apr 1;25(7):858-9. doi: 10.1016/0006-2952(76)90159-3.
9
Dopamine is a monoamine oxidase B substrate in man.多巴胺是人体内单胺氧化酶B的底物。
Nature. 1977 Jan 6;265(5589):80-1. doi: 10.1038/265080a0.
10
The metabolism of amphetamines in mammals.安非他命在哺乳动物体内的代谢。
Drug Metab Rev. 1976;5(2):219-80. doi: 10.3109/03602537609029979.
Zotero 插件